David MD - Nexalin Technology Chief Director
| NXL Stock | USD 3.90 0.08 2.09% |
Insider
David MD is Chief Director of Nexalin Technology
| Age | 62 |
| Address | 1776 Yorktown, Houston, TX, United States, 77056 |
| Phone | (832) 260-0222 |
| Web | https://www.nexalin.com |
Nexalin Technology Management Efficiency
The company has Return on Asset of (1.1892) % which means that on every $100 spent on assets, it lost $1.1892. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (2.0223) %, meaning that it generated no profit with money invested by stockholders. Nexalin Technology's management efficiency ratios could be used to measure how well Nexalin Technology manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -1.38. Return On Capital Employed is expected to rise to -1.69 this year. At this time, Nexalin Technology's Net Tangible Assets are quite stable compared to the past year. Non Current Assets Total is expected to rise to about 212.1 K this year, although the value of Total Current Assets will most likely fall to about 2.6 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Kenneth CPA | Bluejay Diagnostics | 44 | |
| Patrick Mercer | IRIDEX | 52 | |
| Michael Goodman | STRATA Skin Sciences | N/A | |
| Alan Connaughton | LENSAR Inc | 52 | |
| Michael Favet | Neuropace | 54 | |
| Kevin Schmid | Modular Medical | 65 | |
| William MBA | STRATA Skin Sciences | 58 | |
| Keith Simeone | STRATA Skin Sciences | N/A | |
| HuiLan Wu | Ainos Inc | 63 | |
| Christopher Holland | Electromed | 55 | |
| Michael Hutchinson | LivaNova PLC | 53 | |
| Robert Moccia | STRATA Skin Sciences | 65 | |
| Alex Shvartsburg | LivaNova PLC | 54 | |
| Lindsey Little | LivaNova PLC | N/A | |
| Fuad Ahmad | IRIDEX | 54 | |
| Kevin Vance | Bluejay Diagnostics | 66 | |
| Chi Nguyen | Neuropace | 47 | |
| Darrell Rigel | STRATA Skin Sciences | 73 | |
| Christopher Lesovitz | STRATA Skin Sciences | 41 | |
| Kendra Wong | LENSAR Inc | 44 | |
| Mark MD | Bluejay Diagnostics | N/A | |
Management Performance
| Return On Equity | -2.02 | ||||
| Return On Asset | -1.19 |
Nexalin Technology Leadership Team
Elected by the shareholders, the Nexalin Technology's board of directors comprises two types of representatives: Nexalin Technology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nexalin. The board's role is to monitor Nexalin Technology's management team and ensure that shareholders' interests are well served. Nexalin Technology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nexalin Technology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Marilyn Elson, Chief Officer | ||
| Joel Bradus, Director Marketing | ||
| Carolyn Shelton, Regulatory Quality | ||
| Mark White, CEO, President | ||
| David MD, Chief Director | ||
| John Claude, CoFounder Development | ||
| Michael Nketiah, Regulatory Quality |
Nexalin Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nexalin Technology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.02 | ||||
| Return On Asset | -1.19 | ||||
| Operating Margin | (48.32) % | ||||
| Current Valuation | 46.19 M | ||||
| Shares Outstanding | 12.86 M | ||||
| Shares Owned By Insiders | 23.29 % | ||||
| Shares Owned By Institutions | 2.40 % | ||||
| Number Of Shares Shorted | 1.29 M | ||||
| Price To Book | 9.91 X | ||||
| Price To Sales | 327.20 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nexalin Technology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. For more information on how to buy Nexalin Stock please use our How to buy in Nexalin Stock guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nexalin Technology. If investors know Nexalin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nexalin Technology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.65) | Revenue Per Share 0.02 | Quarterly Revenue Growth (0.24) | Return On Assets (1.19) | Return On Equity (2.02) |
The market value of Nexalin Technology is measured differently than its book value, which is the value of Nexalin that is recorded on the company's balance sheet. Investors also form their own opinion of Nexalin Technology's value that differs from its market value or its book value, called intrinsic value, which is Nexalin Technology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nexalin Technology's market value can be influenced by many factors that don't directly affect Nexalin Technology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nexalin Technology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Nexalin Technology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nexalin Technology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.